Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa

Back to Jobs

SAN DIEGO , Jan. 05, 2017 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced positive results from its pivotal Phase 3 clinical trial of

Apply Now